← All trials
NCT04965350
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Jul 16, 2021
- Last posted
- Jul 16, 2021
- Enrollment
- 1100
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Zerun Biotechnology Co.,LtdLead sponsor
- Government of ChinaOverall official - principal investigator
- Shanghai Zerun Biotechnology Co.,LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.